サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1490839

僧帽弁疾患の世界市場-業界分析、規模、シェア、成長、動向、予測（2023年～2030年）

Mitral Valve Disease Market - Global Mitral Valve Disease Industry Analysis, Size, Share, Growth, Trends and Forecast 2023-2030 -

出版日
ページ情報
英文 193 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
僧帽弁疾患の世界市場-業界分析、規模、シェア、成長、動向、予測（2023年～2030年）
出版日: 2024年05月28日
発行: Fairfield Market Research
ページ情報: 英文 193 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

僧帽弁疾患の市場規模は、現在の28億米ドルから2030年までに51億2,000万米ドルに急増するとみられています。市場収益は、2023年から2030年の間にCAGR 9%の高成長が予測されています。

僧帽弁疾患市場は、先天性異常や感染症による僧帽弁問題の有病率の上昇により、大きな拡大を経験しています。先天性の問題は僧帽弁の構造を変化させ、狭窄や逆流などの状態を引き起こす可能性があります。世界人口の高齢化も僧帽弁疾患の有病率の上昇に重要な役割を果たしており、それによって新しい治療に対する需要が高まっています。僧帽弁心臓弁および関連薬剤の開発および承認に関する厳しい規制にもかかわらず、医療技術の進歩は僧帽弁疾患の管理を強化し続けています。

僧帽弁疾患は最も一般的な心臓弁疾患の一つであり、世界中で数100万人が罹患しています。世界保健機関（WHO）によると、世界で約2,600万人が僧帽弁疾患を患っています。この疾患の有病率は年齢とともに増加し、世界人口の高齢化が進むにつれて、効果的な治療に対する需要が高まっています。さらに、糖尿病や肥満のような危険因子は僧帽弁機能不全症の発生率を増加させ、市場をさらに牽引しています。

当レポートでは、世界の僧帽弁疾患市場について調査し、市場の概要とともに、治療タイプ別、適応症別、病期別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • 疾病疫学
  • 規制シナリオ
  • 技術の進歩
  • 疾患診断の情勢
  • 手技件数
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナ・ロシア紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の僧帽弁疾患市場の見通し、2018年～2030年

  • 世界の僧帽弁疾患市場の見通し、治療タイプ別、金額（10億米ドル）、2018年～2030年
  • 世界の僧帽弁疾患市場の見通し、適応症別、金額（10億米ドル）、2018年～2030年
  • 世界の僧帽弁疾患市場の見通し、病期別、金額（10億米ドル）、2018年～2030年
  • 世界の僧帽弁疾患市場の見通し、エンドユーザー別、金額（10億米ドル）、2018年～2030年
  • 世界の僧帽弁疾患市場の見通し、地域別、金額（10億米ドル）、2018年～2030年

第4章 北米の僧帽弁疾患市場の見通し、2018年～2030年

第5章 欧州の僧帽弁疾患市場の見通し、2018年～2030年

第6章 アジア太平洋の僧帽弁疾患市場の見通し、2018年～2030年

第7章 ラテンアメリカ僧帽弁疾患市場の見通し、2018年～2030年

第8章 中東・アフリカの僧帽弁疾患市場の見通し、2018年～2030年

第9章 競合情勢

  • 治療タイプと適応症のヒートマップ
  • 企業市場シェア分析、2022年
  • 競合ダッシュボード
  • 企業プロファイル
    • Abbott Laboratories
    • Medtronic plc
    • Edwards Lifesciences Corporation
    • Boston Scientific Corporation
    • LivaNova PLC
    • Micro Interventional Devices Inc.
    • XELTIS AG
    • Lepu Medical Technology (Beijing) Co. Ltd.
    • CryoLife Inc.
    • Colibri Heart Valve LLC
    • Valcare Medical
    • Affluent Medical
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Bayer AG

第10章 付録

目次

Market Overview

Mitral valve disease market size is set to surge from its current valuation of US$2.8 Bn to US$5.12 Bn by 2030. The market revenue is projected to experience a strong CAGR of 9% between 2023 and 2030.

The mitral valve disease market is experiencing significant expansion, driven by the increasing prevalence of mitral valve issues due to congenital abnormalities and infections. Congenital problems can alter the structure of the mitral valve, leading to conditions such as stenosis or regurgitation. The ageing global population also plays a critical role in the rising prevalence of mitral valve disease, thereby increasing the demand for new treatments. Despite stringent regulatory controls on the development and approval of mitral heart valves and related drugs, advancements in medical technology continue to enhance the management of mitral valve diseases.

Key Market Drivers

1. Growing Prevalence of Mitral Valve Disease: Mitral valve disease is among the most common heart valve conditions, affecting millions worldwide. According to the World Health Organization (WHO), approximately 26 million people globally suffer from mitral valve disease. The prevalence of this condition increases with age, and as the global population continues to age, the demand for effective treatments rises. Additionally, risk factors like diabetes and obesity further drive the market by increasing the incidence of mitral valve dysfunction.

2. Advancements in Technology: Innovations in medical technology and new treatment approaches have significantly improved the management of mitral valve disorders. Devices like the MitraClip, which offer a minimally invasive option for mitral valve repair, reduce mitral regurgitation and alleviate symptoms for patients who are not candidates for traditional surgery. Such technological advancements are driving the adoption of advanced treatments in the mitral valve disease market.

3. Increasing Adoption of Minimally Invasive Techniques: The demand for minimally invasive techniques for treating mitral valve disorders is growing. The development of devices like the Intrepid transcatheter mitral valve replacement (TMVR) system, which utilizes a minimally invasive transfemoral access approach, exemplifies this trend. These innovations are expected to propel market growth as they provide effective alternatives to traditional surgical procedures.

Market Challenges

1. High Costs Associated with Mitral Valve Replacement: The high cost of mitral valve replacement and repair surgeries poses a significant barrier to market growth. The cost of these procedures can vary based on factors such as disease severity, the type of procedure, and the healthcare facility. The financial burden associated with these surgeries can limit their accessibility, especially in lower-income regions.

2. Potentially Unfavorable Health Consequences: Regulatory restrictions imposed by governing bodies on the use, approval, and development of mitral heart valves and medications also hinder market growth. Strict guidelines must be followed during the production of mitral valve repair, replacement, and cardiac resynchronization devices to ensure their safety and quality. These regulations can slow down the development and commercialization of new treatments.

Emerging Trends and Opportunities

1. Growing Screening and Awareness Initiatives: Enhanced awareness campaigns, early diagnosis programs, and increased patient screening efforts are positively impacting the market. Early diagnosis by healthcare professionals improves the likelihood of successful treatments and enhances patient outcomes. Increased awareness leads to higher demand for advanced treatments, contributing to market growth.

2. Increasing Demand for Targeted Therapies and Personalized Medicine: Personalized medicine approaches, which tailor treatments based on individual patient characteristics and disease severity, have the potential to improve treatment outcomes and patient satisfaction. The integration of genetic testing and biomarker analysis into treatment decisions can optimize therapy approaches and drive market growth.

3. Expanding Presence of Key Companies: Collaborations between companies and healthcare organizations, along with exploring underserved regions for expansion, offer significant growth opportunities. Companies can increase market penetration by expanding product portfolios and distribution networks, creating a more competitive market landscape.

Regional Market Leaders

North America: North America is expected to hold the largest market share for mitral valve disease during the forecast period. The region's advanced healthcare system, increased consumer awareness, and high prevalence of mitral valve diseases contribute to this dominance. The rapid adoption of transcatheter mitral valve repair and replacement technology, along with significant improvements in minimally invasive procedures, is driving market growth in North America.

Asia-Pacific: The Asia-Pacific region is projected to experience the highest growth rate, driven by a large population base and rising purchasing power in countries like China and India. The booming pharmaceutical industry in these countries further supports this trend, making Asia-Pacific a key player in the global mitral valve disease market.

Europe: Europe also shows significant growth potential, driven by a well-established healthcare infrastructure and increased funding for the research and development of advanced treatments. European nations are focusing on developing cutting-edge medical technologies and personalized medical strategies, contributing to market growth.

In conclusion, the global mitral valve disease market is set for substantial growth, driven by the rising prevalence of mitral valve problems, technological advancements, and the increasing adoption of minimally invasive techniques. Addressing regulatory challenges and potential health risks will be crucial for sustaining growth and maximizing the market's potential.

Competitive Analysis

  • Abbott Laboratories
  • Medtronic plc
  • Edwards Lifesciences Corporation
  • Boston Scientific Corporation
  • LivaNova PLC
  • Micro Interventional Devices Inc.
  • XELTIS AG
  • Lepu Medical Technology (Beijing) Co. Ltd.
  • CryoLife Inc.
  • Colibri Heart Valve LLC
  • Valcare Medical
  • Affluent Medical
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Bayer AG

Global Mitral Valve Disease Treatment Market is Segmented as:

By Treatment Type

  • Mitral Valve Repair
  • Mitral Valve Replacement
  • Cardiac Resynchronization Therapy
  • Mitral Valve Therapeutics
    • Diuretics
    • Anticoagulants
    • Hypertension Drugs

By Indication

  • Mitral Valve Stenosis
  • Mitral Valve Prolapse
  • Mitral Valve Regurgitation

By Stage

  • Stage C
  • Stage D

By End User

  • Hospitals
  • Specialty Clinics

By Geographic Coverage:

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Turkey
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Egypt
    • Nigeria
    • Rest of Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Mitral Valve Disease Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Disease Epidemiology
  • 2.4. Regulatory Scenario
  • 2.5. Technology Advancement
  • 2.6. Disease Diagnostics Landscape
  • 2.7. Number of procedures
    • 2.7.1. Mitral Valve Repair
    • 2.7.2. Mitral Valve Replacement
  • 2.8. Value Chain Analysis
  • 2.9. Porter's Five Forces Analysis
  • 2.10. COVID-19 Impact Analysis
    • 2.10.1. Supply
    • 2.10.2. Demand
  • 2.11. Impact of Ukraine-Russia Conflict
  • 2.12. Economic Overview
    • 2.12.1. World Economic Projections
  • 2.13. PESTLE Analysis

3. Global Mitral Valve Disease Market Outlook, 2018 - 2030

  • 3.1. Global Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Mitral Valve Repair
      • 3.1.1.2. Mitral Valve Replacement
      • 3.1.1.3. Cardiac Resynchronization Therapy
      • 3.1.1.4. Mitral Valve Therapeutics
        • 3.1.1.4.1. Diuretics
        • 3.1.1.4.2. Anticoagulants
        • 3.1.1.4.3. Hypertension Drugs
  • 3.2. Global Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Mitral Valve Stenosis
      • 3.2.1.2. Mitral Valve Prolapse
      • 3.2.1.3. Mitral Valve Regurgitation
  • 3.3. Global Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. Stage C
      • 3.3.1.2. Stage D
  • 3.4. Global Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospitals
      • 3.4.1.2. Specialty Clinics
  • 3.5. Global Mitral Valve Disease Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Mitral Valve Disease Market Outlook, 2018 - 2030

  • 4.1. North America Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Mitral Valve Repair
      • 4.1.1.2. Mitral Valve Replacement
      • 4.1.1.3. Cardiac Resynchronization Therapy
      • 4.1.1.4. Mitral Valve Therapeutics
        • 4.1.1.4.1. Diuretics
        • 4.1.1.4.2. Anticoagulants
        • 4.1.1.4.3. Hypertension Drugs
  • 4.2. North America Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Mitral Valve Stenosis
      • 4.2.1.2. Mitral Valve Prolapse
      • 4.2.1.3. Mitral Valve Regurgitation
  • 4.3. North America Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. Stage C
      • 4.3.1.2. Stage D
  • 4.4. North America Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospitals
      • 4.4.1.2. Specialty Clinics
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 4.5.1.2. U.S. Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 4.5.1.3. U.S. Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 4.5.1.4. U.S. Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 4.5.1.5. Canada Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 4.5.1.6. Canada Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 4.5.1.7. Canada Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 4.5.1.8. Canada Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Mitral Valve Disease Market Outlook, 2018 - 2030

  • 5.1. Europe Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Mitral Valve Repair
      • 5.1.1.2. Mitral Valve Replacement
      • 5.1.1.3. Cardiac Resynchronization Therapy
      • 5.1.1.4. Mitral Valve Therapeutics
        • 5.1.1.4.1. Diuretics
        • 5.1.1.4.2. Anticoagulants
        • 5.1.1.4.3. Hypertension Drugs
  • 5.2. Europe Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Mitral Valve Stenosis
      • 5.2.1.2. Mitral Valve Prolapse
      • 5.2.1.3. Mitral Valve Regurgitation
  • 5.3. Europe Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Stage C
      • 5.3.1.2. Stage D
  • 5.4. Europe Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Specialty Clinics
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.2. Germany Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 5.5.1.3. Germany Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 5.5.1.4. Germany Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 5.5.1.5. U.K. Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.6. U.K. Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 5.5.1.7. U.K. Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 5.5.1.8. U.K. Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 5.5.1.9. France Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.10. France Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 5.5.1.11. France Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 5.5.1.12. France Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 5.5.1.13. Italy Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.14. Italy Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 5.5.1.15. Italy Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 5.5.1.16. Italy Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 5.5.1.17. Turkey Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.18. Turkey Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 5.5.1.19. Turkey Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 5.5.1.20. Turkey Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 5.5.1.21. Russia Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.22. Russia Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 5.5.1.23. Russia Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 5.5.1.24. Russia Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 5.5.1.25. Rest of Europe Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.26. Rest of Europe Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 5.5.1.27. Rest of Europe Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 5.5.1.28. Rest of Europe Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Mitral Valve Disease Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Mitral Valve Repair
      • 6.1.1.2. Mitral Valve Replacement
      • 6.1.1.3. Cardiac Resynchronization Therapy
      • 6.1.1.4. Mitral Valve Therapeutics
        • 6.1.1.4.1. Diuretics
        • 6.1.1.4.2. Anticoagulants
        • 6.1.1.4.3. Hypertension Drugs
  • 6.2. Asia Pacific Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Mitral Valve Stenosis
      • 6.2.1.2. Mitral Valve Prolapse
      • 6.2.1.3. Mitral Valve Regurgitation
  • 6.3. Asia Pacific Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. Stage C
      • 6.3.1.2. Stage D
  • 6.4. Asia Pacific Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Specialty Clinics
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.2. China Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 6.5.1.3. China Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 6.5.1.4. China Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 6.5.1.5. Japan Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.6. Japan Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 6.5.1.7. Japan Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 6.5.1.8. Japan Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 6.5.1.9. South Korea Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.10. South Korea Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 6.5.1.11. South Korea Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 6.5.1.12. South Korea Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 6.5.1.13. India Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.14. India Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 6.5.1.15. India Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 6.5.1.16. India Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 6.5.1.17. Southeast Asia Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.18. Southeast Asia Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 6.5.1.19. Southeast Asia Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 6.5.1.20. Southeast Asia Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 6.5.1.21. Rest of Asia Pacific Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.22. Rest of Asia Pacific Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 6.5.1.23. Rest of Asia Pacific Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 6.5.1.24. Rest of Asia Pacific Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Mitral Valve Disease Market Outlook, 2018 - 2030

  • 7.1. Latin America Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Mitral Valve Repair
      • 7.1.1.2. Mitral Valve Replacement
      • 7.1.1.3. Cardiac Resynchronization Therapy
      • 7.1.1.4. Mitral Valve Therapeutics
        • 7.1.1.4.1. Diuretics
        • 7.1.1.4.2. Anticoagulants
        • 7.1.1.4.3. Hypertension Drugs
  • 7.2. Latin America Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Mitral Valve Stenosis
      • 7.2.1.2. Mitral Valve Prolapse
      • 7.2.1.3. Mitral Valve Regurgitation
  • 7.3. Latin America Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Stage C
      • 7.3.1.2. Stage D
  • 7.4. Latin America Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Specialty Clinics
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.2. Brazil Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 7.5.1.3. Brazil Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 7.5.1.4. Brazil Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 7.5.1.5. Mexico Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.6. Mexico Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 7.5.1.7. Mexico Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 7.5.1.8. Mexico Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 7.5.1.9. Argentina Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.10. Argentina Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 7.5.1.11. Argentina Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 7.5.1.12. Argentina Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 7.5.1.13. Rest of Latin America Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.14. Rest of Latin America Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 7.5.1.15. Rest of Latin America Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 7.5.1.16. Rest of Latin America Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Mitral Valve Disease Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Mitral Valve Repair
      • 8.1.1.2. Mitral Valve Replacement
      • 8.1.1.3. Cardiac Resynchronization Therapy
      • 8.1.1.4. Mitral Valve Therapeutics
        • 8.1.1.4.1. Diuretics
        • 8.1.1.4.2. Anticoagulants
        • 8.1.1.4.3. Hypertension Drugs
  • 8.2. Middle East & Africa Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Mitral Valve Stenosis
      • 8.2.1.2. Mitral Valve Prolapse
      • 8.2.1.3. Mitral Valve Regurgitation
  • 8.3. Middle East & Africa Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. Stage C
      • 8.3.1.2. Stage D
  • 8.4. Middle East & Africa Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Specialty Clinics
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.2. GCC Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 8.5.1.3. GCC Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 8.5.1.4. GCC Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 8.5.1.5. South Africa Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.6. South Africa Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 8.5.1.7. South Africa Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 8.5.1.8. South Africa Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 8.5.1.9. Egypt Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.10. Egypt Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 8.5.1.11. Egypt Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 8.5.1.12. Egypt Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 8.5.1.13. Nigeria Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.14. Nigeria Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 8.5.1.15. Nigeria Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 8.5.1.16. Nigeria Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
      • 8.5.1.17. Rest of Middle East & Africa Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.18. Rest of Middle East & Africa Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
      • 8.5.1.19. Rest of Middle East & Africa Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
      • 8.5.1.20. Rest of Middle East & Africa Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Treatment Type vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2022
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Abbott Laboratories
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Medtronic plc
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Edwards Lifesciences Corporation
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Boston Scientific Corporation
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. LivaNova PLC
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Micro Interventional Devices Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. XELTIS AG
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Lepu Medical Technology (Beijing) Co. Ltd.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. CryoLife Inc.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Colibri Heart Valve LLC
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Valcare Medical
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Affluent Medical
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Teva Pharmaceutical Industries Ltd.
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Product Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. Pfizer Inc.
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Product Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Bayer AG
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Product Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations